CHRO Melissa McLaughlin sold 3,910 shares for $1,274,342.99 across 14 transactions at blended $325.92
Melissa McLaughlin, Chief Human Resources Officer at Alnylam Pharmaceuticals, executed 14 separate sales totaling 3,910 shares for $1,274,342.99 between April 2–6, 2026, reducing her post-transaction holdings to 9,443 shares (-29.3% of pre-transaction position). The sales occurred at prices ranging from $316.61 to $333.94, with a blended average of $325.92, compared to the current stock price of $319.52. The stock is currently trading -35.0% below its 52-week high of $491.22 and down 24.4% over the trailing 90 days, providing context for the sale execution. The company reported strong fundamentals with quarterly revenue of $1,249,026,000 and net income of $251,084,000, though the elevated P/E of 66.71 and 65.2% annual revenue growth suggest high growth expectations are already embedded in valuation.